Building upon the platform of CMV-specific CTLs that have been shown to kill CMV-positive GBM, we are studying the safety and efficacy of autologous CMV-specific CTLs expressing a HER2-specific CAR in patients with relapsed or refractory her2-positive, CMV-positive GBM (36). The gene discussed is ERBB2; the disease is glioblastoma.